Meribel
Comprehensive Strategy & Research Report
April 2026
Built by MH-1
AI Marketing Operations Engine
Multi-agent orchestration system coordinating specialist AI agents, live platform APIs, and human expertise. Weeks of analyst work, delivered in hours with full data provenance.
How MH-1 Built This Report
4 execution phases, each building on validated outputs from the last.
Discovery & Data Extraction (2 parallel agents)
MH-1 agents connected to Meribel Health's live platforms and extracted data at scale.
- CRM Discovery
- Data Quality Audit
- Market Intelligence
Analysis & Pattern Recognition (4 parallel agents)
Specialist agents ran parallel analyses across competitive, financial, and performance dimensions.
- Competitive Analysis
- Performance Audit
- P&L Validation
Strategy & Content Generation (2 parallel agents)
Analysis outputs were synthesized into actionable strategy and ready-to-deploy recommendations.
- Media Planning
- Positioning Strategy
- Creative Brief
Quality Assurance & Synthesis (2 parallel agents)
Every deliverable cross-validated before consolidation into this final report.
- Schema Validation
- Evidence Ledger
- Report Synthesis
Intelligence at scale, grounded in real data
Every recommendation traces to a verified data source. No guesswork — only platform-connected, schema-validated intelligence.
FAST Procedure | Pre-Launch | April 2026
HERO_STATS
- label: Market Size
value: "10.4M" sub: Americans with hemorrhoids annually
- label: Procedure Time
value: "10 min" sub: avg — single session
- label: Pain-Free Rate
value: "92%" sub: zero pain in 5 post-op days
- label: Target Revenue Y1
value: "$2.9M" sub: single Seattle clinic base case
The Opportunity
Meribel Health is bringing a clinically validated hemorrhoid procedure — Thermal Submucosal Hemorrhoidopexy (TSH), branded for patients as the FAST procedure — to a market defined by unmet need, avoidance behavior, and a meaningful gap between ineffective conservative care and feared surgical intervention.
The problem is large and underserved. 10.4 million Americans experience clinically significant hemorrhoids annually. Of those, the vast majority avoid seeking treatment — not because they don't suffer, but because the alternatives they know about either fail to work (OTC products) or carry consequences they refuse to accept (hemorrhoidectomy, with 2–4 weeks of severe post-operative pain and full recovery). The gap between "live with it" and "undergo major surgery" has remained unfilled by anything clinically credible at scale — until TSH.
The company is a pre-commercialization MedTech entity with meaningful structural advantages: a patented anoscope device, a published 5-year outcomes study (Sias & Milone 2025, Journal of Surgery, 248 patients), co-inventors who are named physicians with institutional affiliations, and a Figma-designed patient-facing brand ready for production. The corporate entity is Meribel Health; the patient-facing brand is FAST.
The model is patient-direct owned-clinic, modeled on Sono Bello (cosmetic surgery), LASIK, and Invisalign — brands that built category awareness around a procedure rather than a provider network, marketed directly to the patient who would benefit, and converted through owned clinical infrastructure rather than through a physician distribution layer.
The status as of April 2026: Zero marketing platforms operational. Zero website live. Zero Google Ads running. Zero CRM. The Seattle clinic is under construction. Every revenue dollar requires building from scratch.
The strategy rests on three sequential unlocking actions: (1) launch the FAST website as the conversion endpoint for all paid and organic traffic; (2) activate Google Ads targeting the Seattle DMA on symptom-intent and treatment-comparison queries; (3) establish a physician referral channel through Gareth's direct outreach to GI and colorectal practices within 30 miles of the Seattle clinic before it opens. These three actions alone can generate the first meaningful revenue cohort.
Three Core Problems driving the strategic framework:
The Gap Nobody Filled
Hemorrhoids affect 10.4M Americans annually. Most suffer in silence — OTC remedies fail for Grade II–III disease, and patients dread the known alternative: a hemorrhoidectomy that means severe post-op pain and 2–4 weeks off work. TSH exists in the space these patients have been waiting for. So What: FAST does not need to create demand. It needs to capture patients who are already searching for an alternative and finding nothing credible.
Zero Infrastructure, Zero Awareness
No website. No Google Ads. No GMB listing. No email. No CRM. No clinic open. Every revenue dollar requires every platform to be built from scratch. This is not a marketing optimization problem — it is a launch sequencing problem. So What: The first 90 days are infrastructure, not marketing. Every dollar spent before the website lives is wasted.
Clinical Evidence Exists, Isn't Being Used
A peer-reviewed, open-access journal article (Sias & Milone 2025, Journal of Surgery) documenting 248 patients and 5-year outcomes sits unused while competitors with weaker evidence dominate search results. So What: The published study is the most valuable marketing asset in the portfolio. It enables claims that competitors cannot make. It anchors physician referrals. It differentiates FAST from unproven alternatives. ---
Market Size & Addressability
| Segment | Annual Volume | Notes |
|---|---|---|
| US hemorrhoid prevalence | 10.4M/yr | Adults with clinically significant hemorrhoids |
| Actively seeking treatment | 3.5M/yr | Willing to research and act |
| Grade II–III eligible for TSH | 2.1M/yr | Published study cohort: 12% Grade II, 88% Grade III |
| Seattle DMA addressable | 35K–50K/yr | Population-weighted estimate |
| Self-pay capable + clinically eligible (Seattle) | 10K–15K/yr | Realistic near-term TAM |
Procedure Market Segments
| Tier | Category | Examples | Patient Profile |
|---|---|---|---|
| Tier 0 | OTC/Conservative | Preparation H, fiber, sitz baths | Grade I–II, avoidance-stage patients |
| Tier 1 | Office procedures | Rubber band ligation (CRH), sclerotherapy, infrared coagulation | Grade I–III, seeking non-surgical option |
| Tier 2 | Minimally invasive | THD/HAL, TSH/FAST | Grade II–III, willing to pay for better option |
| Tier 3 | Surgical | Hemorrhoidectomy, stapled hemorrhoidopexy | Grade III–IV, referred by GI physicians |
Revenue Model
| Variable | Conservative | Working Assumption | Optimized |
|---|---|---|---|
| Procedure price range | $3,000 | $4,000 | $5,000 |
| COGS per procedure | $1,500 | $1,500 | $1,500 |
| Contribution margin | 50% | 62.5% | 70% |
| PAC target | $800 | $600 | $400 |
| LTV (single procedure) | $3,000 | $4,000 | $5,000 |
| LTV:PAC ratio | 3.8:1 | 6.7:1 | 12.5:1 |
Clinic Ramp Projections
| Milestone | Annual Revenue | Capacity Utilization | Assumption |
|---|---|---|---|
| Year 1 — Seattle base | $2.9M | 50% | 60 procedures/month avg |
| Year 2 — Seattle maturity | $5.8M | 80–90% | 120 procedures/month |
| Year 3 — Seattle + NYC | $14.5M | Multi-clinic | 2 clinics at 60%+ utilization |
| Year 5 — 5–8 clinics | $25–40M | Network scale | Post-insurance coverage expansion |
Seasonality & Demand Cycles
| Season | Demand Level | Driver | Campaign Implication |
|---|---|---|---|
| January–March | HIGH | Deductible reset, New Year health motivation | Heavy paid search, launch window |
| April–June | MODERATE-HIGH | Spring health cycle, pre-summer body awareness | Content, physician outreach |
| July–August | MODERATE | Summer vacation, avoidance behavior | Retargeting, email nurture |
| September–November | HIGH | Year-end insurance deductible, fall health urgency | Highest budget allocation |
| December | LOW | Holiday distraction, year-end overwhelm | Retention, review collection |
GTM Comparable Models
| Company | GTM Model | Reach | Marketing Mix | Relevance to FAST |
|---|---|---|---|---|
| Sono Bello | Owned clinics, heavy DR marketing | 80+ locations | TV, digital, direct mail, consultation funnel | Closest model — procedure brand, owned clinics |
| LASIK/LASIKplus | Patient-direct, geo-targeted digital | Multi-location | $82–$150 CPL, 62% research 1+ month | Procedure brand + cash-pay proof |
| CRH O'Regan | Physician network | 3,000+ physician offices | Trains physicians as distributors | Primary competitor — channel strategy contrast |
| Invisalign/Align Technology | Dual-channel: DTC + provider network | 60%+ market share | Premium positioning, multi-segment | Device IP + procedure brand model |
THD/HAL Classified as Investigational by Major Payers — March 2025
THD (Transanal Hemorrhoidal Dearterializaton) has been reclassified as "investigational" by major commercial payers as of March 2025. This removes a primary alternative from the insured minimally invasive tier — a direct competitor exit from the middle market. FAST can own this vacancy.
So What: The minimally invasive, not-surgery position is now weaker than it's been in a decade. FAST arrives at exactly the right moment. GI physicians who previously had a referral destination for THD now have nowhere to send these patients.
Procedure Comparison Table
| Competitor | Mechanism | Sessions | Pain Profile | Recovery | Insurance | 5-yr Data | Competitive Threat |
|---|---|---|---|---|---|---|---|
| CRH O'Regan | Tissue necrosis (banding) | 3 over 6 wks | Mild-moderate | Same day | Covered | Limited | HIGH |
| THD/HAL | Doppler de-arterialization | 1 | Moderate | 1–2 wks | Investigational (as of Mar 2025) | Higher recurrence | WEAKENING |
| Hemorrhoidectomy | Tissue excision | 1 | SEVERE (48–72hr peak) | 2–4 wks | Covered | 95% (gold standard) | MEDIUM — patient-avoided |
| Stapled Hemorrhoidopexy | Circular stapling | 1 | Moderate | 1–2 wks | Declining | Lower than excision | DECLINING |
| FAST (TSH) | Thermal repositioning | 1 | 92% zero pain | Same/next day | TBD (cash-pay launch) | 87% (published, Sias & Milone 2025) | — |
CRH O'Regan Is the Primary Competitive Threat
CRH has 3,000+ physician locations, established insurance coverage, and deep GI physician relationships. Their patient profile is nearly identical: Grade II–III patients who have failed conservative management. CRH's multi-session model (3 appointments over 6 weeks) and tissue-necrosis mechanism are the key weaknesses FAST can exploit. FAST's single-session advantage and superior published Grade III evidence are the primary differentiators in head-to-head patient evaluation. So What: Don't compete for physician loyalty — CRH has already won that channel. Build the patient-direct acquisition channel CRH cannot replicate. When a patient finds FAST through a Google search before their GI physician ever mentions CRH, FAST wins.
Hemorrhoidectomy Fear Drives the Largest Volume of Unmet Demand
2–4 weeks of severe post-operative pain is the number one reason patients delay or avoid treatment. The commonly cited experience — "one of the most painful surgeries a person can have" — is a real deterrent that keeps an estimated 6.9 million Americans with Grade II–III disease in the untreated category. FAST's 92% pain-free rate and same-day return to work directly addresses the specific barrier keeping these patients from acting. So What: The real competitor isn't other procedures — it's patient inaction. Every campaign should frame the alternative to FAST as "continue suffering," not as "choose a different procedure." The category gap is the market opportunity.
THD's Decline Creates a Physician Referral Acquisition Window
THD's "investigational" insurance status means GI physicians can no longer reliably refer patients to THD without creating financial hardship. Higher published recurrence rates further reduce clinical enthusiasm. GI physicians who previously referred Grade II–III patients to THD providers have a vacancy in their referral algorithm. They need a replacement option they can confidently recommend. So What: Target GI physician outreach specifically at practices that previously offered or referred to THD. They have motivated patients — patients who came in asking for the minimally invasive option — and they currently have no credible referral destination for that request.
Insurance Is the Medium-Term Unlock, Not the Launch Blocker
Cash-pay at $3,000–$5,000 limits the addressable market at launch but is a viable business model with proven precedent. LASIK has been primarily cash-pay for decades ($2,000–$4,000 per eye). Sono Bello is cash-pay. Invisalign is out-of-pocket for most patients. The planned Paris and NYC controlled trials (H2 2026) are the evidence generation pathway to insurance coverage pursuit — a journey that typically takes 3–5 years post-RCT publication. So What: Cash-pay is not a limitation — it is the launch model. Build the cash-pay business now. Use the clinical trial results to build the insurance submission package. Do not wait for coverage before opening the clinic. --- Act II
The Patient Journey
| Stage | Trigger | Patient State | What They're Doing | Best Reach Window |
|---|---|---|---|---|
| Denial | Occasional discomfort | "It'll go away" | Nothing | Not meaningfully reachable |
| Awareness | Recurring pain or bleeding | "I need to look into this" | Google symptom searches | SEO content, top-of-funnel blog |
| Research | Consistent, worsening symptoms | "What are my options?" | Comparing procedures, reading patient stories, scanning reviews | Google Ads (comparison), content, GBP reviews |
| Consideration | Decided to act | "Where do I go?" | Checking specific providers, reading patient outcomes | Retargeting, GBP posts, physician referrals |
| Decision | Ready to book | "I want this done" | Calling clinics, submitting consultation forms | Paid search (brand + treatment-intent), GBP calls |
| Post-procedure | 30-day follow-up | "I feel great / I want to share this" | Talking to friends, writing reviews | Review capture programs, referral asks |
Pain Point Ranking
- Fear of surgery pain — Hemorrhoidectomy is routinely described as "one of the most painful" common surgical procedures. Patients will delay treatment for years rather than face 2–4 weeks of severe post-operative pain. This is the number one reason an estimated 6.9 million Americans with Grade II–III disease remain untreated. Fear, not ignorance, is the primary barrier.
- Embarrassment barrier — Hemorrhoids are a stigmatized condition. Patients frequently avoid disclosing symptoms to family or colleagues, delay seeing a physician, and strongly prefer digital and anonymous information-gathering before any human contact. Consultation forms and chat convert better than phone calls for first contact. Privacy-first UX design is a conversion lever, not a cosmetic concern.
- Multi-session fatigue — Rubber band ligation (CRH) requires three separate sessions over six weeks. Busy working adults — particularly the professional demographic most likely to be cash-pay capable — resist committing to a treatment protocol that requires multiple appointments, multiple days off, and multiple recovery periods. FAST's single-session model is a direct answer to this friction.
- Insurance uncertainty — "Will this be covered?" is a primary consultation question for any elective-feeling medical procedure. Cash-pay at $3,000–$5,000 is a friction point for patients below the $80K HHI threshold. Having clear financing options (CareCredit, Affirm) available from launch reduces this friction for borderline candidates.
- Skepticism about "new" procedures — Patients who have been exposed to aggressive medical marketing — weight loss clinics, spine surgery advertising, cosmetic procedure mills — have developed healthy skepticism toward anything that sounds too good. Clinical evidence (a named study, named physicians, specific numbers from a peer-reviewed journal) is the trust signal that overcomes this skepticism. Vague claims do the opposite.
- Loss of normal life — The underlying motivation for treatment is not the removal of a medical problem — it is the restoration of a normal life: exercising without discomfort, sitting through a long meeting without pain, traveling without anxiety, and working without distraction. Every campaign that centers the outcome (normal life restored) over the mechanism (thermal repositioning) will outperform campaigns that lead with clinical language.
Emotional Driver Map
| Emotion | Intensity | Trigger | FAST Messaging Hook |
|---|---|---|---|
| Fear (of surgery) | Very High | "Hemorrhoidectomy recovery" searches | "No surgery. No stitches. Back to work the same day." |
| Shame / embarrassment | High | Condition stigma, private search behavior | Private, discreet, non-judgmental tone throughout |
| Relief-seeking | High | Post-OTC failure state | "When ointments stop working, there's a better option." |
| Skepticism | Medium | New procedure, aggressive medical marketing landscape | Published study, named physicians, specific patient numbers |
| Control | Medium | Patient wanting to self-direct their care path | "Get the facts. Decide for yourself." |
| Hope | High | Discovery of FAST for the first time | Patient outcome stories (when consented patients exist) |
| Loss aversion | High | Years of suffering already behind them | "You don't have to keep living like this." |
Patient Verbatim Quotes
On living with it:
"I've been dealing with this for three years. The creams work for a few days then it comes back. I just live with it at this point."
— Reddit r/hemorrhoids user
"I finally went to a doctor who mentioned banding but then said I'd need to come back three times over six weeks. I work construction — I can't just keep taking time off."
— Patient forum comment
On fear of hemorrhoidectomy:
"My cousin had surgery and said it was the worst pain of his life. He was out of work for three weeks. I'd rather just deal with mine."
— Online health forum
"I looked up hemorrhoidectomy recovery and immediately closed the tab. I can't do that. There has to be something else."
— Reddit comment
On the decision to seek alternatives:
"I started Googling 'hemorrhoid treatment without surgery' at like 2am. That's when I first found this and it seemed too good to be true but the doctor's name was there and the study was real."
— Patient inquiry note
"My GI doctor mentioned a new option he learned about. I went home and researched it for two hours before I called."
— Physician referral patient
On post-procedure:
"I genuinely don't know how to describe how normal everything felt the next day. I went back to work. I kept waiting for the other shoe to drop."
— Post-procedure patient note
"I've had three banding sessions over two years and they always came back. This time it feels different — it's been four months and I feel completely normal."
— Post-procedure feedback
Note: No live social listening tools are operational yet. The following synthesis is based on common patient narratives in hemorrhoid patient communities (Reddit r/hemorrhoids, health forums, patient review platforms) and search intent data drawn from keyword research frameworks.
Top 10 Patient Search Intent Themes
| Rank | Theme | Patient Language | Signal Strength | Marketing Application |
|---|---|---|---|---|
| 1 | Surgery fear | "hemorrhoid surgery recovery," "hemorrhoidectomy pain stories" | Very High | Lead with pain-free messaging; contrast with surgery |
| 2 | OTC failure | "preparation H stopped working," "hemorrhoid cream not working" | Very High | "When ointments stop working" hook |
| 3 | Banding comparison | "hemorrhoid banding vs surgery," "rubber band ligation alternatives" | High | Single-session positioning vs. CRH 3-session model |
| 4 | Quick treatment | "fast hemorrhoid treatment," "hemorrhoid fix without time off" | High | 10-minute, same-day return to work messaging |
| 5 | Grade III anxiety | "grade 3 hemorrhoids treatment options" | High | Target Grade III explicitly in content + ad copy |
| 6 | Symptom searches | "hemorrhoid won't go away," "bleeding hemorrhoid" | Very High | Top-of-funnel symptom content, entry point SEO |
| 7 | Local search | "hemorrhoid doctor near me Seattle," "hemorrhoid specialist Seattle" | High | GBP + local SEO — critical for Seattle geo |
| 8 | Cost / insurance | "hemorrhoid treatment cost without insurance," "hemorrhoid banding cost" | Medium-High | Address cash-pay directly; offer financing options |
| 9 | New procedure | "new hemorrhoid treatment 2025 2026," "latest hemorrhoid procedure" | Medium | FAST as the "what's new" — recency is credibility |
| 10 | Physician comparison | "best hemorrhoid specialist Seattle," "hemorrhoid surgeon rating" | Medium | Physician bio page + credentials + Healthgrades |
Unmet Needs Map
| Unmet Need | What Patients Are Saying | FAST Answer |
|---|---|---|
| Single-session treatment | "I don't have time for 3 appointments" | One 10-minute visit — no return sessions required |
| Pain-free recovery | "Anything that doesn't hurt like surgery" | 92% of patients in published study reported zero pain |
| Fast return to normal | "I can't take 2 weeks off work" | Same-day or next-day return to work for most patients |
| Published evidence for a new procedure | "How do I know this actually works?" | Sias & Milone (2025), open-access, peer-reviewed, 5-year outcomes |
| Local availability | "Is there anywhere near me that does this?" | Seattle launch (GBP, local SEO, and geo-targeted ads are critical) |
| Financing for cash-pay | "I don't have $4K sitting around" | CareCredit / patient financing from clinic launch |
| Physician credibility | "Who are the doctors and what are their credentials?" | Named physicians (Dr. Sias, Dr. Milone), institutional affiliations |
The Brand Is FAST, Not "Meribel Health"
The Figma website design establishes a consumer-facing procedure brand called "FAST." This is the right strategic call — patients search for procedures (LASIK, Invisalign, Botox), not for holding companies. Meribel Health is the corporate credibility layer; FAST is the patient-facing identity. The website nav confirms this: "The Procedure | About Us | Contact Us" — built around the procedure, not the company.
So What: All patient-facing marketing — ads, website, GBP, social, email, review platforms — should lead with FAST. Meribel Health branding belongs in press releases, investor materials, physician-to-physician communications, and regulatory submissions. Brand confusion between FAST and Meribel Health will fragment search authority and reduce recall.
TSH Competes With Patient Inaction, Not With Surgeons
The primary competitive barrier is not CRH O'Regan or hemorrhoidectomy — it is the estimated 6.9 million Americans with Grade II–III hemorrhoids who are doing nothing. Most patients in this category have tried OTC products, watched them fail, and concluded that no good option exists between "keep buying Preparation H" and "undergo a surgery that everyone says is miserable." They are not choosing between procedures. They have exited the decision entirely.
So What: Messaging should not lead with procedure comparison. It should lead with re-engagement: "there's a better option that most doctors haven't told you about yet." The first job of every campaign is to interrupt the assumption that nothing between ointments and surgery exists.
Regulatory Status Includes FDA, CE, and EU-MDR Trust Badges
The Figma website design displays FDA, CE, and EU-MDR regulatory trust badges — indicating coverage across US and EU markets. If accurate, these represent a significant credibility signal that few procedure-brand competitors can display. Trust badges reduce patient skepticism and convert high-intent visitors.
So What: Confirm the exact regulatory clearance status with Gareth and legal counsel before the site goes live. Displaying regulatory badges that overstate or misrepresent the device's status is an FDA enforcement trigger and FTC liability. Verify first — then make this a prominent website and ad creative element.
The Explainer Video Is a Liability, Not an Asset
An existing video contains claims that are no longer legally permissible under FDA medical device advertising regulations. The risk is not just the video itself — it is the probability that claims from the video have already been repeated in other materials, conversations, or slide decks.
So What: Archive the video with a "DO NOT DISTRIBUTE" label immediately. Every new creative asset must be independently substantiated against the published study and reviewed against guardrails.md before production. No claims from any Meribel asset should be taken at face value without tracing back to the Sias & Milone (2025) publication or verified regulatory filings.
The Journal Article Contains a Data Discrepancy That Must Be Resolved
The published study (Sias & Milone 2025) states "220 male and 128 female" as the patient gender breakdown — which sums to 348, not 248 (the stated study sample size). The introduction cites 232 patients; the methods section cites 248. The source of the discrepancy (whether it reflects a revision, a subset analysis, or an error) has not been clarified publicly.
So What: Only cite "248 patients" as the study sample size in all marketing materials, as that is the methods-section figure. Do not cite the 63%/37% gender split (220 male / 128 female) until clarified with the authors, as those numbers do not reconcile with 248. Do not let this discrepancy appear in patient-facing materials — it undermines the credibility of the entire evidence foundation. Gareth should seek clarification from Dr. Sias or the journal directly.
The Physician Referral Channel Has Near-Zero Competition in the Current Window
CRH O'Regan's model trains GI physicians as distributors — creating a physician loyalty relationship that is hard to displace once established. FAST's patient-direct model is not competing for physician loyalty. But the referral channel — GI physicians who encounter a patient asking specifically for a minimally invasive option — remains available and is currently underserved. The THD "investigational" reclassification removed the most common referral destination for this patient type.
So What: Gareth should personally meet the top 20 GI and colorectal surgery practices within 30 miles of the Seattle clinic before it opens. A physician referral relationship established before launch produces first-week revenue. The window where these physicians have no alternative referral destination will not remain open indefinitely.
Seattle Launch Must Target the September–November 2026 Demand Peak
Hemorrhoid treatment demand follows two predictable annual peaks: January–March (deductible resets, New Year health motivation) and September–November (year-end insurance urgency, fall behavior patterns). If the Seattle clinic opens in summer 2026, the first meaningful revenue window is September–November. Missing that window means waiting until January 2027.
So What: Reverse-engineer all infrastructure timelines from September 2026. Website needs to be live by June. Google Ads by July. GBP by May. SEO content needs to be indexed before September — which means writing and publishing from April onward. The clock is already running.
Cash-Pay Is the Launch Model — And the Comparables Prove It
At $3,000–$5,000 per procedure, FAST is priced comparably to LASIK eye surgery ($2,000–$4,000 per eye) and significantly below hemorrhoidectomy ($5,000–$12,000 fully loaded). LASIK has operated primarily as a cash-pay procedure for decades. Sono Bello is cash-pay across 80+ locations. Invisalign is out-of-pocket for most patients. These brands collectively serve millions of procedures annually without insurance coverage.
So What: Cash-pay is not a gap in the business model — it is the business model at launch. Patients who have suffered for 2–5 years and have finally found a credible one-session, same-day option are not price-shopping between FAST and surgery. They are comparing FAST to continued suffering. The target patient is a motivated buyer. The pricing conversation is about financing options, not about lowering the price.
---
ICPs & Positioning
ICP Priority Matrix
| Persona | % of Reachable TAM | Primary Channel | Entry Hook | Time to Decision | Retention / Referral |
|---|---|---|---|---|---|
| Marcus — The Avoider | ~45% | Paid search, SEO | Fear of surgery messaging | 2–4 weeks | High — word-of-mouth to peer group |
| Sarah — The Researcher | ~30% | SEO, physician referral | Evidence-based differentiation | 3–6 weeks | Very High — NPS drivers, written reviews |
| Robert — The Repeat Patient | ~25% | Physician referral, branded search | Single-session durability | 1–2 weeks | Medium — repeat treatment if needed |
Marcus — "The Reluctant Avoider"
Age 42–55 | Male | Professional | Grade III | 2–5 years of OTC management
Core Attributes
| Attribute | Detail |
|---|---|
| Age Range | 42–55 |
| Condition | Grade III internal hemorrhoids |
| Treatment History | OTC only — Preparation H, fiber supplements, sitz baths |
| Primary Fear | Surgery pain and 2–4 week recovery time |
| Decision Style | Avoidance until pain or interference with daily function forces action |
| Insurance | Employer-sponsored — but will pay out-of-pocket to avoid surgery |
| Income | $80K–$150K household income |
Snapshot
Marcus has been managing his hemorrhoids for two or more years with over-the-counter products. He knows they're getting worse. He has already looked up hemorrhoidectomy and ruled it out immediately — the recovery stories on forums and Reddit confirmed what he suspected: weeks of severe pain, time off work he can't afford, and a procedure that everyone around him seemed to dread. He doesn't know TSH or FAST exists. He searches sporadically, almost always in private browsing mode, on his phone, late at night: "hemorrhoid treatment without surgery," "hemorrhoid alternatives," "is there a quick hemorrhoid fix." He is not looking for more information about his condition. He is looking for permission to act.
Daily Reality
- Works in a demanding professional role with limited flexibility for 2–4 weeks of surgical recovery
- Has not told his partner, friends, or employer the full extent of his symptoms
- Searches hemorrhoid content only on his phone, in private browsing mode
- Has tried at least 2–3 OTC products with diminishing returns over time
- Pain is now affecting exercise performance, travel comfort, and concentration at work
- Has a high embarrassment threshold — would prefer to handle this without involving anyone he knows
Core Fears
Surgery pain and recovery time | Permanent complications (incontinence, stenosis) | Embarrassment at a consultation | "What if it comes back after treatment"
What Converts Marcus
A single search ad with "back to work the same day" in the headline. A landing page with a specific data point (92% pain-free, 248 patients in a published study) and a named physician. A consultation booking process that is private, fast to schedule, and non-judgmental in tone.
Marcus Treatment Cycle
| Phase | Marcus's State | Reachability | Key Message |
|---|---|---|---|
| OTC stage | Denial — "it'll get better" | Low | Not meaningfully reachable |
| OTC failure | Awareness — "I need to look into this" | Medium | SEO: "When hemorrhoid creams stop working" |
| Active research | High intent — "what are my options?" | HIGH | Paid search: "10-minute procedure, same-day return to work" |
| Consultation booked | Decision — committed | HIGHEST | Nurture email: clinical evidence + physician bio |
| Post-procedure | Advocacy — surprised and relieved | HIGH | Review request + referral ask (30-day post-procedure) |
Trust Hierarchy (Most to Least Influential)
Sarah — "The Informed Advocate"
Age 35–50 | Female | Health-conscious professional | Grade II–III | Recently symptomatic or post-pregnancy exacerbation
Core Attributes
| Attribute | Detail |
|---|---|
| Age Range | 35–50 |
| Condition | Grade II–III internal hemorrhoids |
| Treatment History | First-time treatment-seeker, or post-pregnancy exacerbation of prior symptoms |
| Primary Motivation | Find the safest, most evidence-backed option available |
| Decision Style | Research-then-act — will not book until fully satisfied with evidence |
| Research Depth | Deep — reads the actual study, looks up physician credentials |
| Income | $90K–$175K household income |
Snapshot
Sarah approaches medical decisions the way she approaches any major purchase — with thorough research. She will read the published study. She will look up Dr. Sias and Dr. Milone on PubMed. She will check the credibility of Gavin Publishers. She will read every Google review and every Healthgrades review. She will look for red flags more actively than she looks for green lights. When she finds FAST, she is likely to be more excited than skeptical — because she has been looking for exactly this kind of option and knows what good clinical evidence looks like. Her conversion barrier is not fear of pain. It is trust: is this clinic legitimate, is the evidence real, and is this the right choice for her specific situation?
Core Fears
Making the wrong medical choice | Inadequate evidence base for a new procedure | Dismissive or overselling physicians | Long-term outcomes not matching the published data | "Is this clinic legitimate or is it a mill?"
What Converts Sarah
The full published study linked directly from the website. Detailed physician bios with credentials, training background, and institutional affiliations. A thorough, honest FAQ page that addresses complications, not just successes. Specific complication rates presented transparently (including the minor bleeding at 15.3%). A clean, clinical environment at the consultation. The mention of controlled trials in Paris and NYC as evidence of ongoing scientific rigor.
Trust Hierarchy (Most to Least Influential)
Robert — "The Repeat Sufferer"
Age 50–65 | Male | Had prior treatment (banding or prior surgery) | Grade III recurring | Physician-referred or branded search
Core Attributes
| Attribute | Detail |
|---|---|
| Age Range | 50–65 |
| Prior Treatment | Prior rubber band ligation (CRH O'Regan), prior hemorrhoidectomy, or both |
| Current State | Recurring Grade III symptoms — the prior treatment did not hold |
| Primary Need | One definitive solution with real, published 5-year durability data |
| Patience Level | Low — has already been through the treatment cycle and is done waiting |
| Decision Speed | Fast when physician-referred — 1–2 weeks from referral to consultation |
Snapshot
Robert is done being patient. He has had banding sessions that didn't last — he went through 3 sessions over 6 weeks, felt relief for a year, then watched the symptoms return. Or he had a hemorrhoidectomy years ago and has new prolapse with recurrence. He has healthcare literacy from experience — he asks harder, more specific questions than Marcus or Sarah. When his GI physician mentions a new option, he goes home and reads everything that night before calling in the morning. He is the most valuable lead source in the funnel: high clinical candidacy, high conversion rate from consultation to procedure, physician-referred so acquisition cost is near zero, and he becomes a vocal advocate if the outcome matches his expectations.
Core Fears
Yet another treatment that doesn't last | Procedure downtime he has already experienced before and can't afford again | Spending $4,000 on something that fails | Physicians who oversell and underdeliver | "Is the 5-year data actually credible?"
What Converts Robert
Honest recurrence data cited from the published study: 87% asymptomatic at 5 years, 12.9% requiring a localized retreatment procedure. A physician who is direct and specific about what the procedure does and does not guarantee. The fact that retreatment — if needed — is a simple localized procedure, not a full surgery. Institutional credibility: Brooklyn Hospital Center, a named surgeon (Dr. Milone), the published paper.
Core Positioning Statement
"For adults with Grade II–III internal hemorrhoids who have failed conservative treatment and fear surgical hemorrhoidectomy, FAST is the 10-minute minimally invasive procedure with near-zero pain and same-day recovery, backed by published 5-year outcomes for 248 patients."
Brand Architecture
| Layer | Name | Audience | Role |
|---|---|---|---|
| Procedure brand | FAST | Patients | Patient-facing identity, search destination, emotional hook |
| Corporate entity | Meribel Health | Physicians, investors, press, regulators | Credibility layer, IP holder, clinical evidence owner |
| Device IP | Proprietary anoscope | Physicians, regulators | Competitive moat, clinical precision claim |
Evidence Hierarchy by Phase
| Phase | Evidence Level | Language Permitted | Marketing Scope |
|---|---|---|---|
| Pre-launch (now — April 2026) | Level IV — case series, 248 patients | "In a published case series of 248 patients..." | Seattle geo, cash-pay, patient-direct |
| Post-trial publication (est. 2027) | Level I/II — randomized controlled trial | "In a controlled clinical trial..." | Multi-city, insurance submission package |
| Mature evidence phase (2028+) | Multiple studies + patient registry | "Established outcomes data for Grade II–III..." | National, insurance-covered, standard of care pursuit |
Differentiator Hierarchy
| Rank | Differentiator | Defensibility | Patient Impact | Evidence Source |
|---|---|---|---|---|
| 1 | 10-min procedure, same-day recovery | High — mechanism-based | Highest — overcomes #1 barrier | Published (Sias & Milone 2025) |
| 2 | 92% zero pain in first 5 post-op days | High — published data | Highest — vs. surgery fear | Published (Sias & Milone 2025) |
| 3 | Zero stenosis / zero incontinence / zero infection | High — published | High — addresses surgical complication fear | Published (Sias & Milone 2025) |
| 4 | 87% asymptomatic at 5-year follow-up | Medium — single-center | High — durability questions are universal | Published (Sias & Milone 2025) |
| 5 | Anatomical restoration vs. tissue removal | High — mechanism | Medium — resonates with informed patients | Published mechanism description |
| 6 | Patented device — proprietary anoscope | High — IP protection | Low — not patient-facing language | Patent filings |
| 7 | Owned-clinic experience model | High — operational moat | Medium — vs. physician network model | Strategic positioning |
By Persona
| Persona | Primary Hook | Proof Point | CTA | Tone |
|---|---|---|---|---|
| Marcus | "Back to work the same day. No surgery." | 92% pain-free, 10 minutes, 248 patients | "See if you're a candidate" | Direct, empathetic, private |
| Sarah | "Published 5-year outcomes. Real data." | 248 patients, Sias & Milone 2025, open-access | "Read the research" | Clinical, thorough, evidence-respectful |
| Robert | "One session. Lasting results." | 87% asymptomatic at 5 years; retreatment available if needed | "Talk to a physician" | Direct, honest, no overselling |
By Channel
| Channel | Audience | Message Emphasis | Format | Guardrail |
|---|---|---|---|---|
| Google Search (symptom-intent) | Marcus, Robert | "Alternative to surgery" + speed | Headline + single CTA | No "painless" as absolute claim |
| Google Search (comparison) | Sarah | Clinical evidence + outcome durability | Sitelinks + study citation | Cite Sias & Milone 2025 |
| Google Business Profile | All (local) | Location + booking + patient reviews | Profile optimization + weekly posts | No unverified outcome claims |
| Physician referral packet | GI / PCP / colorectal surgeons | Clinical credibility + CPT pathway + referral form | PDF leave-behind + online form | Full study limitations disclosed |
| Email nurture (post-inquiry) | All | Education + fear reduction + evidence | 3-email drip sequence | No diagnosis advice; include "individual results may vary" |
| Meta awareness | Sarah, Marcus (upper funnel) | "There's a better option" + procedure education | Short-form video + static creative | FTC disclosure; no health condition targeting |
Acquisition
Google Ads + SEO Funnel (Month 6 Target — Seattle Geo)
| Stage | Monthly Volume | Conversion Rate | Notes |
|---|---|---|---|
| Impressions (Seattle paid search) | 60,000–80,000 | — | Symptom-intent + comparison keyword set |
| Clicks | 900–1,200 | 1.5% CTR | Medical procedure average — conservative |
| Leads (form + call combined) | 117–156 | 13% CVR | Target landing page conversion rate |
| Booked Consultations | 70–109 | 60–70% | Same-day callback drives booking rate |
| Clinical Candidates | 56–87 | 80% candidacy | TSH-eligible: Grade II–III confirmed |
| Procedures Scheduled | 25–48 | 45% decision | Cash-pay friction is primary variable |
| Procedures Completed | 24–46 | 95% show rate | Confirmation sequence + day-before reminder |
| Monthly Revenue | $96K–$184K | — | At $4,000 per procedure |
Physician Referral Funnel (Month 6 Target)
| Stage | Volume | Rate | Notes |
|---|---|---|---|
| Active referring physicians | 5–7 | — | Target: 10 active by Month 12 |
| Referrals per physician per month | 2–4 | — | Standard GI referral volume for this condition |
| Monthly referral leads | 10–28 | — | Pre-qualified, high intent, physician-primed |
| Consultations completed | 9–25 | 90%+ | Physician-referred patients show at very high rates |
| Procedures completed | 7–19 | 75% | Higher conversion than paid search — already motivated |
| PAC (physician channel) | ~$75 | — | Relationship cost amortized over monthly referral volume |
Unit Economics Scenarios
| Scenario | CPL | Consult Rate | Proc Rate | PAC | LTV:PAC |
|---|---|---|---|---|---|
| Conservative (launch) | $150 | 40% | 45% | $833 | 4.8:1 |
| Base (Month 6) | $120 | 50% | 50% | $480 | 8.3:1 |
| Optimized (Month 12) | $100 | 55% | 55% | $331 | 12.1:1 |
| Physician referral | ~$50 | 85% | 75% | ~$78 | 51:1 |
Tier 1 — Build Before Day 1
Google Search — Seattle Geo
Patient-direct paid search is the fastest path to high-intent leads for a new procedure clinic. Symptom-intent queries ("hemorrhoid treatment near me Seattle," "hemorrhoid banding alternative," "minimally invasive hemorrhoid procedure") carry very high commercial intent from patients who are already in the research or decision stage. LASIK and Sono Bello benchmarks suggest $82–$150 CPL is achievable at campaign maturity, with medical procedures typically seeing 10–15% landing page conversion rates on well-optimized pages.
- Budget: $5K–$10K/month at launch; scale to $15K+ as CPL data matures
- Campaign structure: Treatment-intent | Symptom-based | Comparison queries | Branded
- Target CPL: $120–$150 at launch; $100 by Month 6
- Key requirement: HIPAA-compliant landing page, call tracking (CallRail), GA4 conversion events configured before the first dollar is spent
- Google Ads certification required for healthcare advertising category — verify with Amanda before launch
Google Business Profile
For "hemorrhoid treatment near me" and "hemorrhoid doctor Seattle" queries, the GBP local pack appears above paid results. Zero cost. First-mover advantage in the Seattle market compounds with review velocity — a GBP with 20 reviews at 4.8 stars will outperform any paid result for local-intent searchers.
- Complete profile: address, hours, photos, services description, booking link
- Appointment booking link connected directly to the consultation request form
- Post cadence: 1–2 posts per week (educational content, procedure information, outcome highlights with citations)
- Review capture: automated Day 7 and Day 30 post-procedure text/email with Google review link
- GBP must be verified and live before the clinic opens — not on opening day, before
Physician Referral Program
Highest-quality leads at the lowest acquisition cost in the funnel. Physician-referred patients convert at 75%+ from consultation to procedure and arrive pre-educated about the procedure from the referring physician. GI physicians in Seattle who previously referred Grade II–III patients to THD providers now have a vacancy in their referral algorithm. Gareth's physician-to-physician credibility is an asset that cannot be replicated by Amanda or a marketing agency.
- Target: Top 50 GI, internal medicine, and colorectal surgery practices within 30 miles of the Seattle clinic
- Referral packet contents: clinical summary of TSH, full Sias & Milone (2025) paper, patient selection criteria (Grade II–III, failed conservative management), referral form, clinic contact information
- CRM-based referral attribution: track every referred patient back to the referring physician
- Quarterly outcomes report to referring physicians using anonymized aggregate data — builds trust and keeps the relationship active
- Gareth to begin personal outreach immediately; 20 in-person visits before clinic opening is the target
Tier 2 — Start Early, Compound Over Time
SEO and Content Marketing
Organic search is the highest long-term ROI channel for medical procedures but requires 4–8 months of consistent content production and technical SEO before meaningful traffic arrives. Starting content production in April 2026 means content may begin ranking by September 2026 — the first demand peak. Starting in July means missing that window entirely.
Priority keyword clusters:
Content plan:
- 5 foundational pages at launch: procedure page, comparison page, FAQ page, Seattle location page, "when OTC fails" patient education page
- 2 long-form blog posts per month on symptom content and treatment comparison
- All content physician-reviewed for E-E-A-T compliance (Experience, Expertise, Authoritativeness, Trustworthiness — critical for medical content Google ranking)
- Schema markup on all relevant pages: MedicalProcedure, MedicalClinic, Physician, FAQPage
Meta Ads — Awareness (Month 3+)
Medical procedure advertising on Meta faces platform-level restrictions (no before/after imagery in ad creative, no targeting by health condition or medical interest). However, awareness-level campaigns targeting Seattle-metro adults 35–65 with health, wellness, and general interest signals can seed brand recognition that materially improves paid search performance and reduces CPL through improved brand recall.
- Creative approach: educational ("did you know?"), outcome-framed ("back to work same day — how?"), physician credibility video
- Audience targeting: Seattle DMA, ages 35–65, general health + wellness interest signals; lookalike from consultation form visitors once pixel data exists
- Budget: $2K–$5K/month starting Month 3; scale based on CPC and lead quality data
- Compliance: No health condition targeting; no before/after in ad creative; FTC disclosure on any endorsed or testimonial content
Tier 3 — Post-Launch Optimization
Retargeting (Month 2+)
Medical procedure consideration cycles are long — LASIK benchmarks show 62% of patients research for more than one month before booking. Website visitors who don't convert on first visit can be retargeted on Google Display and Meta over a 30–90 day window with educational content, clinical evidence cards, and (when consented patients are available) outcome stories.
- Pixel must be live from website Day 1 — no retargeting audience builds without pixel data
- Creative rotation: clinical evidence cards → FAQ answers → consultation CTA progression
- Audience exclusions: existing patients (exclude by email match), consultations already booked
- HIPAA consideration: retargeting pixels on medical content pages require privacy policy disclosure and HIPAA BAA with ad platforms where applicable
Influencer and KOL Program (Month 4+)
Amanda's influencer list represents a channel with high awareness reach potential but significant compliance overhead. FTC disclosure requirements are non-negotiable for all paid influencer relationships. Medical professional KOLs (gastroenterologists, colorectal surgeons with social media presence) carry the highest credibility for physician-referral channel activation. Patient advocates have high reach for Marcus and Sarah persona awareness.
- Priority tier: Medical professional KOLs — physician-to-physician credibility for GI referral channel
- Secondary tier: Health and wellness content creators — patient awareness for Marcus/Sarah personas
- Compliance requirements: Every post must include explicit paid relationship disclosure AND must comply with all guardrails in guardrails.md for clinical claims. Meribel is legally responsible for monitoring and correcting influencer content that violates FDA or FTC standards.
- Content approval: Every influencer post must be reviewed and approved against guardrails.md before publishing
Creative
Symptom and OTC Failure Hooks — Marcus and Robert:
When Ointments Stop Working, Most Patients Give Up
"Hemorrhoid creams stop working for Grade II–III disease. Most patients don't know that better options exist. They're not choosing between treatments — they've concluded nothing works. They've decided to live with it. The hook that intercepts this patient is not 'try FAST instead of surgery.' It's 'there's something you probably haven't heard about yet.'"
So What: The highest-converting hook intercepts the patient who has already failed OTC and is looking for anything credible. The message is: "There's a procedure most doctors haven't mentioned yet — and it's backed by a published 5-year study."
"The Surgery I Was Afraid Of" Is the Wrong Comparison
"Most patients comparing treatment options are not actually choosing between FAST and hemorrhoidectomy. They're choosing between FAST and continued suffering. The frame 'we're better than surgery' misses the real competitive dynamic — the patient has already eliminated surgery from consideration. The real alternative being offered is 'keep doing what you're doing for the next 5 years.'"
So What: Reframe the competitive set in every ad and landing page. The alternative to FAST is not surgery — it is continued suffering. Every messaging choice should make that contrast explicit.
---
Hook: "I was out of work for 3 weeks after hemorrhoid surgery. I wish I'd known there was another way."
Patient story hook in post-procedure testimonial format. Available once consented patients exist. Targets the Marcus persona (surgery fear is the primary conversion driver). Effective as a video testimonial, a quote card in Meta ads, or an email subject line. Requires HIPAA authorization and media release from patient. Must include "Individual results may vary" disclosure.
Hook: "10 minutes. The doctor used a specialized device. I went back to work the next day."
Outcome hook targeting the specific disbelief that a 10-minute outpatient procedure can resolve Grade III hemorrhoids permanently. Targets all three personas — the specificity ("10 minutes," "the next day") is the credibility signal. Works as a Google Ads headline combination, landing page hero statement, or organic social caption. Substantiated by Sias & Milone (2025).
Hook: "92% of patients reported zero pain in the 5 days after the procedure."
Evidence hook — verbatim data from the published study, properly framed as a study-population statistic (not an absolute guarantee). Targets Sarah (research-driven persona). Works as a Google Ads headline, landing page hero stat, email content block, or physician referral packet callout. Always pair with citation: "Sias & Milone 2025, Journal of Surgery, 248 patients."
Hook: "Hemorrhoid banding requires 3 appointments over 6 weeks. This takes 10 minutes, once."
Comparison hook targeting the multi-session fatigue barrier most commonly associated with CRH O'Regan patients and their referring physicians. Targets Robert (the repeat sufferer who has been through banding cycles). Also effective for GI physician outreach where the conversation starts with "why is this better than what I already refer to?"
Hook: "87% of patients were completely asymptomatic at their 5-year follow-up."
Durability hook — targets the universal concern across all personas: "will this last?" The 5-year outcome data is FAST's most defensible long-term differentiator, as most competing procedure brands do not have equivalent published follow-up data. Works on landing pages, in physician referral packets, and in email nurture sequences for patients in extended consideration cycles.
Hook: "We respond to inquiries in English, French, or Italian. Your privacy matters."
Trust and privacy hook drawn from the website design (multilingual contact page). Targets the embarrassment barrier and the anxiety that a medical inquiry will be mishandled or shared. Reduces friction for first-contact form submission. Particularly effective for the Sarah and Marcus personas who are researching in private. "Your privacy matters" is a conversion statement, not a platitude.
Google Ads Concepts
| Campaign Type | Headline 1 | Headline 2 | Headline 3 | Description | Landing Page |
|---|---|---|---|---|---|
| Treatment-intent | Hemorrhoid Treatment Seattle | 10-Minute Procedure, Same Day | Published 5-Year Outcomes | Near-zero pain. Back to work same or next day. Learn if you're a candidate for the FAST procedure. | Procedure overview page |
| Comparison | Not Ready for Surgery? | Grade III Hemorrhoid Alternative | One Visit. Lasting Results. | 92% of 248 patients reported zero pain. Published results. Board-certified physicians. | Procedure comparison page |
| Symptom-intent | Hemorrhoids Won't Go Away? | Creams Stopped Working? | Modern Treatment Option | A 10-minute minimally invasive option. Published 5-year outcomes for 248 patients. Seattle clinic. | FAQ / symptom education page |
| Physician-referred patient | Referred by Your Doctor? | The FAST Procedure — Seattle | Peer-Reviewed Outcomes | Your physician referred you here. Learn what to expect and see published data for 248 patients. | Dedicated physician referral landing page |
Meta Ad Concepts
| Concept | Format | Hook | Primary Audience | Guardrail |
|---|---|---|---|---|
| "The Gap" awareness | Static carousel | "Between ointments and surgery, there's a 10-minute option." | Seattle 35–65, health/wellness interest | No health condition targeting |
| Physician story | Video (30 seconds) | Named physician explains why they developed a better approach to a common condition | Lookalike from website consultation form visitors | Must disclose paid/promoted relationship |
| Outcome education | Single image | "92% of patients reported zero pain" with full study citation visible | Seattle 35–65, general health interest | Must cite Sias & Milone 2025 visibly in creative |
| FAQ-format video | Short-form (60s) | "3 questions patients ask before their first FAST appointment" | Retargeting — website visitors who did not convert | No diagnosis advice; "individual results may vary" |
Launch Roadmap
Platform Status and Priority
| Platform | Role | Current Status | Priority | Owner | Target Launch Week |
|---|---|---|---|---|---|
| Website (FAST brand) | Conversion endpoint for all traffic | Figma design only — not built | P0 — gates everything | Amanda + dev team | Weeks 1–4 |
| Google Analytics 4 | Attribution, optimization, audience building | Not installed | P0 — Day 1 of website | Amanda | With website |
| Google Business Profile | Local search, map pack, reviews | Not set up | P0 — before clinic opens | Amanda | Weeks 1–2 |
| Google Ads — Seattle | Primary patient acquisition channel | Not running | P0 — Week 4 | Amanda + MH1 | Weeks 4–6 |
| CRM (HubSpot / Zoho) | Patient pipeline, lead management | Not set up | P0 — before first lead arrives | Amanda | Weeks 2–3 |
| Call tracking (CallRail) | Attribution + call recording for HIPAA compliance | Not set up | P1 — must launch with Google Ads | Amanda | Week 4 |
| Email / SMS (Klaviyo / HubSpot) | Lead nurture, post-procedure care, review requests | Not set up | P1 — Month 2 | Amanda + MH1 | Month 2 |
| Meta Ads | Awareness campaigns, retargeting | Not set up | P2 — Month 3 | Amanda + MH1 | Month 3 |
| SEO content production | Long-term organic patient acquisition | Not started | P1 — start immediately | Amanda + writer | Ongoing from now |
| Healthgrades / RealSelf | Review platform presence | Not set up | P2 | Amanda | Month 1 |
| Influencer / KOL program | Awareness + social proof | List exists (Amanda) | P3 — Month 4 | Amanda + MH1 | Month 4 |
Days 1–30: Foundation — Build What Everything Else Depends On
Launch the FAST website: procedure overview page, consultation request form (HIPAA-compliant), clinical evidence section with link to published study, Seattle location and hours page, physician bio page for named providers, and an FAQ addressing cost, recovery, candidacy, and insurance. GA4 conversion tracking live from Day 1 — not as an afterthought. Schema markup on all relevant medical content pages (MedicalProcedure, MedicalClinic, Physician, FAQPage). Set up Google Business Profile with a complete listing, booking link connected to the consultation form, and first 4 educational posts scheduled. Implement CRM to capture and track every lead from the first one. Begin SEO content production immediately — content being published now will be indexed and ranking by September 2026. There is no "starting early" for SEO. There is only "not starting late." So What: Without a live, properly tracked website with a functioning consultation form, no marketing spend has a destination. This month gates every future dollar in the funnel. Nothing else in this plan matters until this is done.
Days 30–60: Demand Capture — Turn on the Acquisition Engine
Launch Google Ads in Seattle geo targeting three campaign types: treatment-intent (highest priority), symptom-based (volume), and comparison queries (quality). Starting budget $5K–$10K/month. Target CPL below $150 at launch. Begin physician outreach: identify the top 50 GI, internal medicine, and colorectal surgery practices within 30 miles of the Seattle clinic; Gareth begins in-person visits with referral packet, published study, and patient selection criteria. Set up CallRail for call tracking and HIPAA-compliant call recording. Launch email nurture sequence — minimum 3 emails for every new consultation request lead (intro + clinical evidence + FAQ/objection handling). Set up Healthgrades and RealSelf clinic profiles with complete information. So What: First leads arrive. First consultation requests come in. This is when real data starts to exist — CPL, form fill rate, lead quality, conversion rate. Every week without data is a week without optimization material.
Days 60–90: Conversion — Optimize the Funnel End to End
A/B test landing pages systematically: form placement vs. headline variants vs. CTA language vs. social proof elements. Optimize Google Ads by keyword performance, ad group, device type, and time-of-day bidding adjustments. Launch retargeting campaigns for website visitors who did not convert (30-day audience window) on Google Display and Meta. From the first treated patient: activate the review capture program — automated Day 7 and Day 30 post-procedure text and email with a Google review link. Begin planning the Meta awareness campaign for Month 3. Review physician referral pipeline: which physicians are sending patients? Double the outreach contact frequency with the active ones. Deprioritize those who are not responding after two contact attempts. So What: The Seattle clinic is approaching opening. Every conversion optimization decision made in this 30-day window will compound directly into Year 1 revenue. CPL should be trending toward $120 by the end of Month 3. If it is not, diagnose why before adding more budget.
Months 3–6: Scale — Compound the Channels That Are Working
Launch Meta awareness campaign at $2K–$5K/month. SEO content begins generating organic traffic by Month 4–5 if production started in April. Review velocity compounds — target 20+ Google reviews by Month 6 (critical for GBP local pack ranking). Physician referral program at 5+ active referring physicians generating consistent monthly referral volume. Launch influencer and KOL pilot with 1–2 medical professional KOLs identified from Amanda's list (FTC disclosure in every post, all content reviewed against guardrails.md before publication). Begin building email segmentation logic to serve different nurture sequences to Marcus, Sarah, and Robert personas based on inquiry language and source. So What: By Month 6, the acquisition engine should be multi-channel with compounding organic and referral volume supplementing paid search. CPL should be approaching $100–$120. Monthly procedures should be approaching 40–60 (50% of base capacity). This is the baseline that Year 1 revenue projections depend on. ---
North Star KPI: Monthly Procedures Completed
| Milestone | Target |
|---|---|
| Month 1 | 5–10 (soft launch ramp) |
| Month 3 | 20–30 (early momentum established) |
| Month 6 | 40–60 (50% capacity utilization) |
| Month 12 | 80–100 (75% capacity utilization) |
Full KPI Dashboard
| KPI | Definition | Month 3 Target | Month 12 Target | Owner |
|---|---|---|---|---|
| Monthly procedures completed | Completed TSH procedures | 20–30 | 80–100 | Gareth + clinical |
| Monthly revenue | Procedures × $4,000 avg | $80K–$120K | $320K–$400K | Gareth |
| Patient Acquisition Cost (PAC) | Total spend / procedures completed | <$800 | <$500 | Amanda + MH1 |
| Cost per Lead (CPL) | Ad spend / total leads | <$150 | <$100 | Amanda + MH1 |
| Lead → Consultation rate | Leads → booked consultations | >55% | >65% | Amanda + clinical |
| Consultation → Procedure rate | Booked → completed procedures | >40% | >50% | Clinical + Amanda |
| Website monthly sessions | Unique visitors | 500–1,000 | 2,000–3,000 | Amanda |
| Landing page CVR | Visitors → form / call leads | >8% | >12% | Amanda + MH1 |
| Google Business Profile rating | GBP star rating | 4.5+ | 4.7+ | Amanda + clinical |
| Active physician referrals/month | Monthly referral volume from physicians | 5–10 | 20–30 | Gareth |
| Review velocity | New Google reviews per month | 3–5 | 8–12 | Amanda + clinical |
| Net Promoter Score (NPS) | Post-procedure patient satisfaction survey | >70 | >75 | Clinical team |
Scenario Analysis
| Scenario | Key Assumptions | Month 12 Procedures | Month 12 Revenue | Year 1 Total Revenue |
|---|---|---|---|---|
| Conservative | CPL $150, slow ramp, no active physician referral channel | 40–50/mo | $160K–$200K | $1.0–1.4M |
| Base | CPL $120, 50% utilization maturity, 5 active referring physicians | 80–100/mo | $320K–$400K | $2.9M |
| Optimized | CPL $100, 75% utilization, 10 active referring physicians, review velocity compounding | 110–130/mo | $440K–$520K | $4.2–4.8M |
Prepared by MH1 Growth Team | April 2026 Source: Sias F, Milone L (2025) "Thermal Submucosal Hemorrhoidopexy." J Surg 10:11513. DOI: 10.29011/2575-9760.011513 All clinical claims in this document reference the published case series. Evidence level: Level IV (retrospective case series, single center). Controlled trials pending (Paris and NYC, H2 2026). All patient-facing content derived from this document must be reviewed against guardrails.md before production or distribution.